Halozyme Clears $103 as CEO Had Sold at $80
Halozyme Therapeutics reported Q2 2026 EPS of $2.28, beating the $1.82 estimate by 25%, as trailing twelve-month revenue grew 42.2% to $1.51 billion. CEO Helen Torley executed 19 open-market sales at
Halozyme Shares Clear $100 as CEO Sold at $80
NEW YORK, August 8 —
Halozyme Therapeutics, Inc. (HALO) shares surged past $103 after Q2 2026 results landed August 6, eclipsing the $88.22 analyst consensus and approaching TD Cowen's freshly raised $105 target. That puts the stock well above the $64, $80 price range where CEO Helen Torley made 19 open-market sales in the three preceding months, with zero insider purchases across the same period.
- Q2 2026 EPS $2.28 vs. $1.82 estimate, a 25% beat; TTM revenue $1.51B, up 42.2%; gross margin 76.7%.
- CEO Torley sold in 19 transactions at $64.63, $80.19; aggregate insider net sales $7.74M, zero purchases.
- Stock at $103.12, above $88.22 consensus; 14.5% short interest; TD Cowen raised price target to $105.
The Selling Pattern
From May 11 through July 8, 2026, Torley sold in tight clusters: mid-May at $64.63, $73.12, early June at $66.31, $69.69, and July 8 at $79.28, $80.19 per share. Each cluster was paired with option exercises at $12.07. Her largest single transaction was 16,600 shares at $66.31 on June 2, totaling approximately $1.10 million. Director Mahesh Krishnan sold 7,304 shares at $75.00 on June 29. Across all insiders, the 90-day period produced $7.74 million in net sales and zero open-market purchases.
What the Business Delivered
Halozyme is a drug delivery licensing business, not a drug company. Its ENHANCE technology, centered on the rHuPH20 enzyme, converts IV biologics to subcutaneous form, reducing infusion center visits for partners' patients. The franchise covers DARZALEX SC (Janssen's multiple myeloma treatment), Ocrevus SC (Roche's multiple sclerosis therapy), and Phesgo (Roche's breast cancer combination), plus products from Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, and argenx. Q2 2026 results, filed in an August 6 8-K, showed EPS of $2.28 against a $1.82 estimate, a 25% beat. Trailing twelve-month revenue grew 42.2% to $1.51 billion, with a 76.7% gross margin and $677 million in operating cash flow.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HALO | $12.2B | 9.9x | +64.0% |
| NBIX | $16.6B | 13.4x | +31.8% |
| PTCT | $6.1B | 29.3x | +69.3% |
| AGIO | $1.9B | n/a | -8.0% |
| ALNY | $29.3B | 17.4x | -49.6% |
| CYTK | $10.4B | n/a | +131.0% |
Two Dollars From the Ceiling
At 10.1x forward earnings, the stock sits within $2 of TD Cowen's $105 ceiling with limited room for further analyst-driven rerating. Running the royalty-stream trajectory through a DCF calculator reveals the constraint: the business carries $2.18 billion in debt against $0.32 billion in cash, and trailing free cash flow was $228 million. Short interest at 14.5% of the float means a Q3 royalty miss on DARZALEX SC or Ocrevus SC would amplify any move lower. The clearest signal to watch: whether Torley or any other insider appears on the buy side at prices where they were recently sellers.
Run the free Halozyme Therapeutics, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Halozyme stock rise past $103?
Halozyme reported Q2 2026 EPS of $2.28 against a $1.82 consensus estimate, a 25% beat, with trailing twelve-month revenue up 42.2% to $1.51 billion at a 76.7% gross margin. The result prompted TD Cowen to raise its price target to $105, and the stock moved to $103.12, above the prior $88.22 consensus.
Did Halozyme insiders buy or sell shares before Q2?
CEO Helen Torley made 19 open-market sales from May 11 through July 8, 2026, at prices ranging from $64.63 to $80.19 per share, each paired with option exercises at $12.07. Across all insiders, the 90-day period produced $7.74 million in net sales and zero open-market purchases.
What is Halozyme's ENHANCE technology?
ENHANCE is centered on the rHuPH20 enzyme, which converts intravenous biologics to subcutaneous form, reducing infusion center visits for partners' patients. Partners include Janssen, Roche, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, and argenx.
What is Halozyme's short interest?
Short interest stood at 14.5% of the float. The article notes that a Q3 royalty miss on DARZALEX SC or Ocrevus SC would amplify any move lower given that level of short positioning.
What is the analyst price target for Halozyme?
TD Cowen raised its price target to $105 following the Q2 results. With the stock at $103.12, it sits within $2 of that ceiling, leaving limited room for further analyst-driven rerating.
Halozyme Therapeutics shares surged past $103 after the company filed Q2 2026 results on August 6, pushing the stock above the $88.22 consensus analyst price target. The rally arrives after CEO Helen Torley sold shares in 19 separate transactions at prices between $64 and $80 — before the move.